Technical Analysis for OXB - Oxford Biomedica Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -0.98% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -0.98% | |
| Multiple of Ten Bullish | Other | -0.98% | |
| Gapped Up | Strength | -0.98% | |
| 50 DMA Support | Bullish | 6.62% | |
| Multiple of Ten Bullish | Other | 6.62% | |
| Down 3 Days in a Row | Weakness | 6.62% |
| Alert | Time |
|---|---|
| Up 1% | about 18 hours ago |
| Reversed from Down | about 19 hours ago |
| Expansion Pivot Entry | about 19 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| Gap Down Closed | about 21 hours ago |
Get a Trading Assistant
Oxford Biomedica Plc Description
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Pipe Diseases Xf Therapy Cell Therapy Cancers Parkinson's Disease Platform Technology Gene Delivery Bioprocessing Cell Therapy Product Viral Vector Virotherapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 474.28 |
| 52 Week Low | 164.288 |
| Average Volume | 285,682 |
| 200-Day Moving Average | 248.00 |
| 50-Day Moving Average | 189.35 |
| 20-Day Moving Average | 199.72 |
| 10-Day Moving Average | 201.41 |
| Average True Range | 9.68 |
| RSI (14) | 54.75 |
| ADX | 22.23 |
| +DI | 21.26 |
| -DI | 13.29 |
| Chandelier Exit (Long, 3 ATRs) | 180.63 |
| Chandelier Exit (Short, 3 ATRs) | 213.04 |
| Upper Bollinger Bands | 208.77 |
| Lower Bollinger Band | 190.67 |
| Percent B (%b) | 0.68 |
| BandWidth | 9.06 |
| MACD Line | 2.63 |
| MACD Signal Line | 3.27 |
| MACD Histogram | -0.6413 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 215.00 | ||||
| Resistance 3 (R3) | 215.33 | 211.67 | 213.00 | ||
| Resistance 2 (R2) | 211.67 | 208.61 | 211.50 | 212.33 | |
| Resistance 1 (R1) | 207.33 | 206.72 | 209.50 | 207.00 | 211.67 |
| Pivot Point | 203.67 | 203.67 | 204.75 | 203.50 | 203.67 |
| Support 1 (S1) | 199.33 | 200.61 | 201.50 | 199.00 | 194.33 |
| Support 2 (S2) | 195.67 | 198.72 | 195.50 | 193.67 | |
| Support 3 (S3) | 191.33 | 195.67 | 193.00 | ||
| Support 4 (S4) | 191.00 |
